{
    "brief_title": "Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy",
    "phase": "Phase 3",
    "drugs": "['Paclitaxel', 'Cisplatin', 'Epirubicin', 'Cyclophosphamide', '5-fluoruracil']",
    "drugs_list": [
        "Paclitaxel",
        "Cisplatin",
        "Epirubicin",
        "Cyclophosphamide",
        "5-fluoruracil"
    ],
    "diseases": "['Invasive Ductal Breast Cancer', 'Tubular Breast Cancer', 'Mucinous Breast Cancer', 'Inflammatory Breast Cancer']",
    "diseases_list": [
        "Invasive Ductal Breast Cancer",
        "Tubular Breast Cancer",
        "Mucinous Breast Cancer",
        "Inflammatory Breast Cancer"
    ],
    "enrollment": "290.0",
    "inclusion_criteria": "inclusion criteria: \n\n Women aged \u226518years and \u226470 years; \n\n Patients with locally advanced breast caner and had weekly paclitaxel and cisplatin as neoadjuvant chemotherapy. \n\n Patients with pathological partial response or pathological complete response to neoadjuvant chemotherapy according to the Response Evaluation Criteria in Solid Tumors (RECIST). \n\n Endocrine therapy and trastuzumab were allowed to use. \n\n ECOG 0-2; \n\n Adequate bone marrow function:WBC\u22654.0\u00d7109/L, Absolute neutrophil count\uff08ANC\uff09\u22651.5\u00d7109/L, Platelets\uff08PLT\uff09\u2265100\u00d7109/L, Hemoglobin\uff08Hb\uff09\u226590g/L;aspartate aminotransferase(AST),Alanine aminotransferase (ALT)\u22641.5 upper normal limit (UNL), creatinine\u22641.5 UNL, bilirubin\u22641.5UNL; \n\n No obvious main organs dysfunction. \n\n ",
    "exclusion_criteria": ": \n\n Unwilling or unable to use an acceptable method of contraception in 8 weeks (including 8 weeks) after final dose of test drug; \n\n Patient is pregnant or breast feeding; \n\n Metastatic breast cancer; \n\n Any evidence of sense or motor nerve disorders; \n\n Patients with medical conditions taht indicate intolerant to neoadjuvant therapy, including uncontrolled cardiovascular disease, severe infection; \n\n Any concurrent malignancy other than breast cancer; \n\n Know severe hypersensitivity to any drugs in this study.",
    "brief_summary": "This trial will compare the administration of 2 cycles of paclitaxel and cisplatin (DP) versus 4 cycles of CEF as adjuvant chemotherapy for the patients with locally advanced breast cancer and who were pathological partial response to DP as neoadjuvant chemotherapy. Those who had pathological complete response to DP will be randomized to have 2 cycles of DP or have no further chemotherapy.",
    "NCT_ID": "NCT02879513"
}